15.71
-0.05
(-0.32%)
At close: April 17 at 5:35:43 PM GMT+2
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Cash Flow
6,554,000
6,554,000
6,768,000
7,403,000
7,952,000
Investing Cash Flow
-1,229,000
-1,229,000
-1,595,000
-8,772,000
-1,777,000
Financing Cash Flow
-4,726,000
-4,726,000
-5,641,000
823,000
-7,589,000
End Cash Position
3,403,000
3,403,000
2,858,000
3,425,000
3,819,000
Capital Expenditure
-2,982,000
-2,982,000
-2,344,000
-2,258,000
-2,654,000
Issuance of Capital Stock
20,000
20,000
10,000
25,000
21,000
Issuance of Debt
1,341,000
1,341,000
223,000
2,046,000
301,000
Repayment of Debt
-2,507,000
-2,507,000
-2,593,000
-6,668,000
-2,304,000
Free Cash Flow
3,572,000
3,572,000
4,424,000
5,145,000
5,298,000
12/31/2021 - 12/1/2003
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
C43.DE Cosmo Pharmaceuticals N.V.
51.50
-1.90%
GIS.DE Gilead Sciences, Inc.
91.92
-1.61%
IDP.DE Biogen Inc.
103.05
-0.67%
4AB.DE AbbVie Inc.
152.40
-0.39%
SNW.DE Sanofi
90.51
+0.11%
BRM.DE Bristol-Myers Squibb Company
43.60
-0.65%
ORNAV.HE Orion Oyj
48.96
-0.48%
ZEG.DE AstraZeneca PLC
118.75
-0.92%
AMG.DE Amgen Inc.
242.30
-4.78%
6MK.DE Merck & Co., Inc.
68.90
+0.44%